Synthetic Biologic Form News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Synthetic biologic form. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Synthetic Biologic Form Today - Breaking & Trending Today

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Published: Apr 14, 2021
ROCKVILLE, Md., April 14, 2021 /PRNewswire/
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). Broad spectrum intravenous (IV) beta-lactam antibiotics used to treat infection following conditioning chemotherapy for allogeneic HCT patients is a necessary and oftentimes lifesaving intervention. However, antibiotic-mediated damage of the gut microbiome in this patient population has been strongly associated with adverse outcomes including ....

United States , Erik Dubberke , Stevea Shallcross , Marka Schroeder , Washington University , Safety Monitoring Committee , Synthetic Biologics Inc , Division Of Oncology , Prnewswire Synthetic Biologics Inc , Clinical Director , Transplant Infectious Diseases , Washington University School , Chief Executive Officer , Associate Professor , Bone Marrow Transplantation , Synthetic Biologics , Synthetic Biologic , Private Securities Litigation Reform Act , Synthetic Biologic Form , ஒன்றுபட்டது மாநிலங்களில் , மார்க்கா ஸ்க்ரோடர் , வாஷிங்டன் பல்கலைக்கழகம் , பாதுகாப்பு கண்காணிப்பு குழு , செயற்கை உயிரியல் இன்க் , பிரிவு ஆஃப் புற்றுநோயியல் , மருத்துவ இயக்குனர் ,

Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Published: Dec 22, 2020

ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received approval from the Institutional Review Board (IRB) at Washington University School of Medicine in St. Louis (Washington University), to commence the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients. As a result, the Company expects to commence patient enrollment for the Phase 1b/2a clinical trial in the first quarter of 2021. ....

United States , Stevena Shallcross , Washington University , Safety Monitoring Committee , Louis Washington University , Synthetic Biologics Inc , Washington University School Of Medicine , Synthetic Biologics , Institutional Review Board , Washington University School , Chief Executive , Financial Officer , Synthetic Biologic , Private Securities Litigation Reform Act , Synthetic Biologic Form , ஒன்றுபட்டது மாநிலங்களில் , வாஷிங்டன் பல்கலைக்கழகம் , பாதுகாப்பு கண்காணிப்பு குழு , லூயிஸ் வாஷிங்டன் பல்கலைக்கழகம் , செயற்கை உயிரியல் இன்க் , வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து , செயற்கை உயிரியல் , நிறுவன விமர்சனம் பலகை , வாஷிங்டன் பல்கலைக்கழகம் பள்ளி , தலைமை நிர்வாகி , நிதி அதிகாரி ,